Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 3:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 6,755 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CHANGE Study Clear all

Conditions: Chronic Disease, Mental Disorder, Health Behavior, Bipolar Disorder, Schizophrenia
Interventions: Prioritized Clinical Decision Support; Behavioral
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10,347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Duluth, Minnesota • Minneapolis, Minnesota

Conditions: Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions: Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide, Cyclosporine, Diagnostic Imaging Testing, Echocardiography Test, Fludarabine Phosphate, Multigated Acquisition Scan, Mycophenolate Mofetil, Survey Administration, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation; Procedure · Drug · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 6 Months to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Alcohol Drinking
Interventions: Brief advice, Health coaching; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 75 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Major Depression, Treatment
Interventions: Sertraline, Cognitive Behavioral Therapy; Drug · Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Noonan Syndrome
Interventions: Vosoritide Injection; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2041
U.S. locations: 21
States / cities: Los Angeles, California • Orange, California • Aurora, Colorado + 18 more

Conditions: Intimate Partner Violence
Interventions: ROSE Program; Behavioral
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years and older · Female only
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Fluid Retention Tissue, Perfusion; Complications
Interventions: Manual Lymphatic Drainage, Near infrared spectroscopy, Temperature, Tissue Dialectic Constant; Other · Device
Lead sponsor: Nova Southeastern University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Diabetes Mellitus
Interventions: Self-efficacy for diabetes management; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Chronic Lymphocytic Leukemia
Interventions: Ublituximab, Umbralisib, Ibrutinib, Venetoclax, Acalabrutinib Oral Capsule; Drug
Lead sponsor: TG Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Boston, Massachusetts • Hackensack, New Jersey • New York, New York

Conditions: Schizophrenia
Interventions: Placebo, Cariprazine; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 765 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 25
States / cities: Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 20 more

Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: Postop IMRT for head/neck cancer, CT for Radiation Treatment Planning; Radiation · Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obstructive Sleep Apnea, Comorbid Insomnia and Sleep Apnea, Insomnia
Interventions: Digital Cognitive Behavioral Therapy (CBT-i)-COAST; Device
Lead sponsor: Thomas Kaffenberger; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cardiac Arrest
Interventions: Amiodarone Hydrochloride Injection, Usual Care Protocol; Drug · Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 585 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Anorexia Nervosa
Interventions: Donepezil; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Defects, Congenital
Interventions: Rejuvesol, Cardiac surgery; Drug · Procedure
Lead sponsor: Duke University; Other
Eligibility: Up to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Colorectal Cancer
Interventions: Decision Aid, Provider Education, Performance Measure Modification, Simple Informational Booklet; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 70 Years to 75 Years
Enrollment: 436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Keloid, Scleroderma, Localized, Acne Keloidalis, Scars, Granuloma Annulare
Interventions: UVB Irradiation; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 10 Years to 80 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pneumococcal Immunization
Interventions: PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine, RotaTeq, Vaxelis vaccine, Varivax, Hexaxim Vaccine; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 42 Days to 89 Days
Enrollment: 1,714 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 66
States / cities: Glendale, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 48 more

Conditions: HIV, HIV Infection
Interventions: SB-728-T; Biological
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 4
States / cities: Los Angeles, California • Newport Beach, California • San Francisco, California + 1 more

Conditions: Melanoma
Interventions: Talimogene laherparepvec; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 11
States / cities: Tampa, Florida • Indianapolis, Indiana • Louisville, Kentucky + 8 more

Conditions: Multiple Sclerosis
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2080
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-Hodgkin's Lymphoma
Interventions: ABT-199, Rituximab, Bendamustine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 8
States / cities: La Jolla, California • Los Angeles, California • Atlanta, Georgia + 5 more

Conditions: APDS
Interventions: Leniolisib; Drug
Lead sponsor: Pharming Technologies B.V.; Industry
Eligibility: 1 Year to 6 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • Bethesda, Maryland • Shaker Heights, Ohio + 1 more

Conditions: Androgen Insensitivity Syndrome, Metabolic Parameters in AIS, CAIS, PAIS and MAIS, Tumor Formation in AIS, CAIS, PAIS and MAIS, Sexual Function AIS, CAIS, PAIS and MAIS
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 8 Years to 99 Years
Enrollment: 650 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2040
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Reducing Cardiovascular Risk in Adults With Serious Mental Illness

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

Alcohol Screening and Pre-Operative Intervention Research Study

fMRI Study of Treatment Changes in Major Depression

A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment

Intervention for IPV Perinatal Women- RCT

Weightlessness Associated Cephalad Fluid Shifts; The Potential to Evaluate Venous and Lymphatic Dysfunction

Stories for Change: Digital Storytelling as a Tool for Engagement in Facilitated Discussion for Diabetes

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia

Prospective Trial of Serial CT Imaging for Evaluation of Dosimetric/Volumetric Changes During IMRT for Head/Neck Cancer

Does the Timing of Insomnia Therapy (CBT-i) Impact the Usage and Compliance of Upper Airway Stimulation (UAS) Treatment of Obstructive Sleep Apnea (OSA)

Early Amiodarone in Shockable Cardiac Arrest

An Open Trial of a Novel Pharmacotherapy for Habit Modification in Anorexia Nervosa

Rejuvenated, Washed Packed Red Blood Cells in Pediatric Cardiac Surgery

Promoting Veteran-Centered Colorectal Cancer Screening

Ultraviolet B (UVB) Light Therapy in the Treatment of Skin Conditions With Altered Dermal Matrix

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Study of Autologous T-cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases in HIV-Infected Subjects

Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec

Pathological Basis of MRI Signal Changes in Multiple Sclerosis

A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

Pediatric Patients Aged 1 to 6 Years With APDS

Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen Insensitivity